Daewoong Pharmaceutical announced that its operating profit on a separate basis last year was 163.8 billion KRW, an increase of 23% compared to the previous year.
According to the disclosure made the day before, Daewoong Pharmaceutical's sales last year rose 3.6% to 1.2654 trillion KRW. Net profit decreased by 61% to 43.16 billion KRW. Daewoong Pharmaceutical stated that both sales and operating profit last year were record highs.
Daewoong Pharmaceutical said that botulinum toxin 'Nabota', gastroesophageal reflux disease new drug 'Pexuclu', and diabetes new drug 'Enblo' drove this performance. Nabota sales last year reached 186.4 billion KRW, a 27% increase compared to the previous year. Exports accounted for 84% of the sales. Pexuclu achieved combined domestic and global sales of over 100 billion KRW last year. During the same period, Enblo sales exceeded 10 billion KRW for the first time.
Daewoong Pharmaceutical stated that it will focus on digital healthcare and innovative new drugs as growth engines. Recently, the smart bed monitoring system 'Think' became the first domestically produced digital healthcare device to obtain insurance reimbursement for 'Remote Heart Rate Monitoring Technology' (EX871). The idiopathic pulmonary fibrosis treatment candidate 'Versiporosin', which is being developed aiming for an innovative new drug, was previously designated by the U.S. Food and Drug Administration (FDA) as an orphan drug and a fast track development item.
Lee Chang-jae, CEO of Daewoong Pharmaceutical, said, "The three major innovative new drugs, Pexuclu, Enblo, and Nabota, led the growth," adding, "We will continue to invest in the digital healthcare market and promote continuous development of innovative new drugs."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
